Avelumab drug aliquots can be used for in vitro or in vivo experiments. For biosimilar development, different batches of Avelumab drug can be ordered at the same time. Several other reference drugs are also available.
The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.
Find and order your therapeutic molecules through smart filters
Up to 10 batches of original drugs for examining batch-to-batch variations
Up to 80% less compared to the original pharmaceutical price
Shipment within days worldwide according to GDP-standards
Up to 80% less compared to the original pharmaceutical price
| Drug name | Bavencio® |
| INN | Avelumab |
| API type | Avelumab is a human monoclonal IgG1 antibody directed against the immunomodulatory cell surface ligand protein PD-L1 and produced in Chinese hamster ovary cells by recombinant DNA technology. |
| Pharmacotherapeutic group | Antineoplastic agents, monoclonal antibodies |
| ATC code | L01XC31 |
| Target of antibody | PD-L1; Synonyms: CD274, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, A530045L16Rik, B7h1, Pdcd1l1, Pdcd1lg1, Pdl1, RGD1566211 |
| General function | Avelumab is used to treat adults with Merkel cell carcinoma (MCC), a rare type of skin cancer when it is metastatic (has spread to other parts of the body). PD-L1 is found on the surface of MCC cells and helps protect tumour cells from the immune system (the body’s natural defences). Avelumab binds to PD-L1, and blocks this protective effect, allowing the immune system to attack the tumour cells. (Source EMA , package leaflet) |
| Short description | |
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | Avelumab is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against programmed death ligand 1 (PD-L1). Avelumab binds PD-L1 and blocks the interaction between PD-L1 and the programmed death 1 (PD-1) and B7.1 receptors. This removes the suppressive effects of PD-L1 on cytotoxic CD8+ T-cells, resulting in the restoration of anti-tumour T-cell responses. |
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | Avelumab has also shown to induce natural killer (NK) cell-mediated direct tumour cell lysis via antibody-dependent cell-mediated cytotoxicity (ADCC). |
| Original license holder | Merck Europe B.V. |
| Marketing authorisation numbers | EU/1/17/1214/001 |
| Marketing authorisation holder | Merck Europe B.V. Gustav Mahlerplein 102 1082 MA Amsterdam The Netherlands |
| Name of the manufacturer of the biological active substance | Merck Serono SA Succursale de Corsier-sur-Vevey Chemin du Fenil - Zone Industrielle B, 1804 Corsier-sur-Vevey Switzerland |
| Name and address of the manufacturer(s) responsible for batch release | Merck Serono S.p.A. Via Delle Magnolie 15 (loc. frazione Zona Industriale) 70026 - Modugno (BA) Italy |
| Max shelf life | 24 months |
| Storage conditions | 2°C – 8°C |
| List of excipients | Mannitol Glacial acetic acid Polysorbate 20 Sodium hydroxide |
Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.
Evidentic GmbH
Am Mühlenberg 10
14476 Potsdam | Germany
